Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2023 08:00 ET | Source: Locanabio, Inc.

Locanabio Announces Presentation of Preclinical Data Demonstrating an Improved Vectorized snRNA Platform with Applications in Exon Skipping for the Potential Treatment of Duchenne Muscular Dystrophy (DMD) at the 28th Annual Congress of the World Muscle Society (WMS2023)

Locanabio presents preclinical data on improved vectorized snRNA platform for exon skipping for the potential treatment of DMD at WMS2023
September 25, 2023 16:01 ET | Source: Locanabio, Inc.

Locanabio Announces Participation in Chardan’s 7th Annual Genetic Medicines Conference

SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative...
May 16, 2023 06:00 ET | Source: Locanabio, Inc.

Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
May 15, 2023 08:00 ET | Source: Locanabio, Inc.

Locanabio Announces Equity Investment from CureDuchenne Ventures to Support Development of snRNA Exon Skipping Approach for Duchenne Muscular Dystrophy (DMD)

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative...
May 02, 2023 16:30 ET | Source: Locanabio, Inc.

Locanabio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

Locanabio to report preclinical data from snRNA exon skipping program in DMD and Cas13d-mediated C9orf72 ALS program SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Locanabio, Inc., a genetic medicines...
April 20, 2023 08:00 ET | Source: Locanabio, Inc.

Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)

Preclinical data from LBIO-115 exon 51 program demonstrate superior levels of exon-skipping that result in high levels of dystrophin restoration Data presented at the CureDuchenne FUTURES 2023...